labcorp america hold
labcorp america lead provid diagnost test inform servic
buyer lh follow solid result appear
overshadow sequenti declin drug develop net book-to-bil
think overblown lh face headwind pama
net neg term lost exclus versu addit
aetna etc believ compani well posit navig
annual free cash flow gener labcorp pois take advantag
pama-rel disloc consolid diagnost market
felt acut year progress continu believ
open aetna contract lh apt
squeez lab add growth year covanc
cost reduct chiltern synergi target plan think share under-
valu maintain buy rate tweak price target
result nutshel ep higher
consensu revenu effect in-lin
consensu estim driven upsid
diagnost drug develop revenu ep guidanc
narrow previou rang
labcorp diagnost revenu modestli ahead
estim test volum increas
forecast upsid organ volum growth vs
estim contribut vs estim revenu
per requisit decreas vs estim pama
character bp headwind price consist past
commentari manag full year view act partial
off-set foreign currenc bp tailwind similar
covanc drug develop revenu y/i
slightli consensu higher estim
fx provid bp tailwind constant currenc
increas function high-singl digit organ growth chiltern
acquisit ttm net order increas slightli sequenti though
net book-to-bil declin sequenti part
function stronger dollar impact fx translat well
sound like measur shift within clinic
central lab compon drug discoveri lh expect
backlog convert revenu next month metric
